DDInter1055 DDInter708
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Levofloxacin {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Ezogabine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ezogabine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Abiraterone
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) upregulates {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Ezogabine
Levofloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP2A6
CYP2A6 {u} (Gene) is bound by {v} (Compound) Ezogabine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Nephrolithiasis
Nephrolithiasis {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Ezogabine
Levofloxacin {u} (Compound) downregulates {v} (Gene) PTPRO
PTPRO {u} (Gene) is regulated by {v} (Gene) UGT1A9
UGT1A9 {u} (Gene) is bound by {v} (Compound) Ezogabine
Levofloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Ezogabine
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is treated by {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Levofloxacin (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Levofloxacin (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Levofloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ezogabine
Levofloxacin (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Abiraterone (Compound) and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) upregulates UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Ezogabine (Compound)
Levofloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Ezogabine (Compound)
Levofloxacin (Compound) causes Nephrolithiasis (Side Effect) and Nephrolithiasis (Side Effect) is caused by Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Ezogabine
Levofloxacin (Compound) downregulates PTPRO (Gene) and PTPRO (Gene) is regulated by UGT1A9 (Gene) and UGT1A9 (Gene) is bound by Ezogabine (Compound)
Levofloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is treated by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine